Yumanity Therapeutics Inc (NASDAQ:YMTX)

1.80
Delayed Data
As of Nov 30
 -0.005 / -0.28%
Today’s Change
0.95
Today|||52-Week Range
4.39
-39.36%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$19.3M

Company Description

Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. It is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. Its platform is based on technology, which enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which usually results from an aberrant accumulation of misfolded proteins in the brain. The company was founded by Susan Lindquist and Tony Coles in December 2014 and is headquartered in Boston, MA.

Contact Information

Yumanity Therapeutics, Inc.
40 Guest Street
Boston Massachusetts 02135
P:(617) 409-5300
Investor Relations:

Employees

Shareholders

Other institutional9.98%
Individual stakeholders9.33%
Mutual fund holders12.08%

Top Executives

Richard PetersPresident, Chief Executive Officer & Director
Michael D. WyzgaChief Financial Officer, Treasurer & Senior VP
Brigitte RobertsonChief Medical Officer
Daniel TardiffResearch Head
Devin W. SmithSecretary, Senior Vice President & General Counsel